Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent

Agarwal, Abhinav; Gupta, Umesh; Asthana, Abhay; Jain, Narendra Kumar

doi:10.1016/j.biomaterials.2009.03.016

Cited by 110 publications

(67 citation statements)

References 28 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Shielding/locking of DOX and primary amine groups in the dendritic architecture due to folic acid surface modification was possibly the reason for reduction of RBCs lysis. The results are similar to the previous reports of surface conjugated dendrimers [51,53]. Agarwal et al [51,53] investigated dextran conjugated PPI G5 dendrimers as nanoscale DOX delivery units (PAD-PPI-DOX).…”

Section: Ways To Reduce Dendrimer Haemotoxicitysupporting

confidence: 89%

“…The results are similar to the previous reports of surface conjugated dendrimers [51,53]. Agarwal et al [51,53] investigated dextran conjugated PPI G5 dendrimers as nanoscale DOX delivery units (PAD-PPI-DOX). PAD-PPI-DOX also demonstrated lower haemolytic activity than an equivalent concentration of PPI G5 or free drug.…”

Section: Ways To Reduce Dendrimer Haemotoxicitysupporting

confidence: 89%

“…In comparison to the PAMAM G4 dendrimer, the modified compounds exhibited lower haemolytic activity, which proved that covering of the cationic groups on the dendrimer surface greatly reduced their negative influence on RBCs. It has also been proved that modified dendrimers can reduce haemolytic activity of encapsulated drugs [49][50][51][52]. Gupta et al [50] reported the design, synthesis and characterization of PPI-FA-DOX, which is a folic acid (FA) conjugated PPI G5 dendrimer encapsulated with doxorubicin (DOX), an effective anticancer drug.…”

Section: Ways To Reduce Dendrimer Haemotoxicitymentioning

confidence: 99%

See 2 more Smart Citations

Influence of dendrimers on red blood cells

Ziemba

Matuszko

Bryszewska

et al. 2012

Cellular and Molecular Biology Letters

View full text Add to dashboard Cite

Dendrimers, highly branched macromolecules with a specific size and shape, provide many exciting opportunities for biomedical applications.However, most dendrimers demonstrate toxic and haemolytic activity because of their positively charged surface. Masking the peripheral cationic groups by coating them with biocompatible molecules is a method to reduce it. It was proven that modified dendrimers can even diminish haemolytic activity of encapsulated drugs. Experiments confirmed that anionic dendrimers are less haemotoxic than cationic ones. Due to the high affinity of dendrimers for serum proteins, presence of these components in an incubation buffer might also influence red blood cell (RBC)-dendrimer interactions and decrease the haemolysis level. Generally, haemotoxicity of dendrimers is concentration-, generation-, and time-dependent. Various changes in the RBCs' shape in response to interactions with dendrimers have been observed, from echinocytic transformations through cell aggregation to cluster formation, depending on the dendrimer's type and concentration. Understanding the physical and chemical origins of dendrimers' influences on RBCs might advance scientists' ability to construct dendrimers more suitable for medical applications.

show abstract

Section: Ways To Reduce Dendrimer Haemotoxicitysupporting

confidence: 89%

Section: Ways To Reduce Dendrimer Haemotoxicitysupporting

confidence: 89%

Section: Ways To Reduce Dendrimer Haemotoxicitymentioning

confidence: 99%

See 1 more Smart Citation

Influence of dendrimers on red blood cells

Ziemba

Matuszko

Bryszewska

et al. 2012

Cellular and Molecular Biology Letters

View full text Add to dashboard Cite

show abstract

“…This specifies the enhanced bioavailability and localized action of the formulation at tumor sites, subsequently augmenting the therapeutic potential by endowing with the prospective to lower the dose of drug requisite for its delivery. The above outcomes may be accredited to the altered vasculature of the tumor mass (Agarwal et al, 2009). Thus, the present formulation utilizes targeting potential and EPR effect for greater accessibility and prolonged retention to these highly leaky and porous architectures.…”

Section: Biodistribution Study Ofmentioning

confidence: 99%

“…Once accumulated, they can act as a local drug depot depending upon the make-up of the carrier, thus providing a source for continuous supply of encapsulated therapeutic compound into tumor mass (Agarwal et al, 2009). Active targeting can be accomplished exploiting specific interaction between receptors on the cell surface and tailoring ligands to the polymer backbone.…”

Section: Introductionmentioning

confidence: 99%